Bg pattern

VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet:information for the user

Vaxigrip Tetra, injectable suspension in a pre-filled syringe

Influenza vaccine (tetravalent, inactivated, split virion)

Read all of this leaflet carefully before you or your child are vaccinated because it contains important information for you or your child.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This vaccine has been prescribed to you or your child, do not pass it on to others, even if their symptoms are the same, as it may harm them.
  • If you or your child experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Contents of the package leaflet

  1. What is Vaxigrip Tetra and what is it used for
  2. What you need to know before you or your child start using Vaxigrip Tetra
  3. How to use Vaxigrip Tetra
  4. Possible side effects

5 Storage of Vaxigrip Tetra

  1. Package contents and additional information

1. What is Vaxigrip Tetra and what is it used for

Vaxigrip Tetra is a vaccine.

This vaccine is given to you or your child from 6 months of age and is intended to protect you or your child against influenza.

When Vaxigrip Tetra is injected into a person, the immune system (the body's natural defense system) will produce protection (antibodies) against infection.

When the vaccine is administered during pregnancy, it not only protects the pregnant woman but also protects her baby from birth to 6 months of age through the transmission of protection from mother to baby during pregnancy (see also sections 2 and 3).

None of the components of the vaccine can cause influenza.

The use of Vaxigrip Tetra should be based on official recommendations.

Influenza is a disease that can spread rapidly and is caused by different types of strains that can change each year. Due to this potential change in circulating strains each year, as well as the duration of the protection provided by the vaccine, vaccination is recommended every year. There is a higher risk of getting influenza during the cold months between October and March. If you or your child did not get vaccinated in the fall, it is possible to get vaccinated until spring, since you or your child are at risk of getting infected with influenza during that period. Your doctor will be able to recommend the best date for vaccination.

The goal of Vaxigrip Tetra is to protect you or your child against the four strains of the virus contained in the vaccine after about 2 to 3 weeks of injection. The incubation period of influenza is a few days, so if you or your child are exposed to influenza immediately before or after vaccination, you or your child may develop the disease.

The vaccine will not protect you or your child against the common cold, even if some of the symptoms are similar to influenza.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using Vaxigrip Tetra

To ensure that Vaxigrip Tetra is suitable for you or your child, it is important that you consult your doctor or pharmacist if any of the points described below apply to you or your child. If there is something you do not understand, consult your doctor or pharmacist to clarify it.

Do not use Vaxigrip Tetra

  • If you or your child are allergic to:
  • The active substances or
  • Any of the other components of this vaccine (listed in section 6), or
  • Any of the components that may be present in minimal amounts, such as eggs (ovoalbumin or chicken proteins), neomycin, formaldehyde, or octoxinol-9.
  • If you or your child have a disease that is accompanied by high or moderate fever or an acute disease, in this case, vaccination will be delayed until you or your child have recovered.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to use Vaxigrip Tetra.

Consult your doctor before getting vaccinated if you or your child have:

  • A weakened immune system (immunodeficiency or treatment with medications that affect the immune system),
  • Bleeding problems or bruising easily.

Your doctor will decide if you or your child should receive the vaccine. Before or after any injection, fainting (especially in adolescents) may occur, so you should inform your doctor or nurse if you or your child have fainted after receiving an injection in the past.

Like all vaccines, Vaxigrip Tetra may not fully protect all people who are vaccinated.

Not all babies under 6 months of age born to women vaccinated during pregnancy will be protected.

If, for any reason, you or your child have a blood test a few days after influenza vaccination, please inform your doctor. This is because false-positive results have been observed in serological tests in some recently vaccinated patients.

Children

Vaxigrip Tetra is not recommended for use in children under 6 months of age.

Use of Vaxigrip Tetrawithother medicines

Tell your doctor or pharmacist if you or your child are using, have recently used, or might use any other medicine or vaccine.

  • Vaxigrip Tetra can be administered at the same time as other vaccines, in different limbs.
  • The immune response may be reduced in the case of immunosuppressive treatments, such as corticosteroids, cytotoxic medications, or radiation therapy.

Pregnancy andbreast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, consult your doctor or pharmacist before using this vaccine.

Vaxigrip Tetra can be used in all stages of pregnancy.

Vaxigrip Tetra can be used during breast-feeding.

Your doctor/pharmacist will be able to decide if you should be vaccinated with Vaxigrip Tetra.

Driving and using machines

Vaxigrip Tetra has a negligible influence on the ability to drive and use machines.

Vaxigrip Tetra contains potassium and sodium

This medicine contains less than 1 mmol of potassium (39 mg) and less than 1 mmol of sodium (23 mg) per dose; that is, it is "essentially potassium-free" and "sodium-free".

3. How to use Vaxigrip Tetra

Dosage

Adults: 1 dose of 0.5 ml.

Use in children

Children from 6 months to 17 years of age receive a dose of 0.5 ml.

If your child is under 9 years of age and has not been previously vaccinated against influenza, a second dose of 0.5 ml should be administered after an interval of at least 4 weeks.

If you are pregnant, a dose of 0.5 ml administered during pregnancy may protect your baby from birth to 6 months of age. For more information, ask your doctor or pharmacist.

How Vaxigrip Tetra is administered

Your doctor or nurse will administer the recommended dose of the vaccine with an injection into the muscle or under the skin.

If you or your child receive more Vaxigrip Tetra than you should

In some cases, more doses than recommended were administered by mistake.

In these cases, when adverse events were reported, they were in line with those described after administration of the recommended dose (see Section 4).

If you have any doubts about the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

Allergic reactions

Contact your doctor or healthcare professional or go immediately to the Emergency Department of the nearest hospital if you or your child experience allergic reactions (reported as rare: may affect up to 1 in 1,000 people) that can be life-threatening. Symptoms may include skin rash, itching, hives, redness, difficulty breathing, shortness of breath, swelling of the face, lips, throat, or tongue, cool and clammy skin, palpitations, dizziness, weakness, or fainting.

Other side effects reported in adults and the elderly

Very common (may affect more than 1 in 10 people)

  • Headache, muscle pain (myalgia), general feeling of being unwell (malaise) (1), pain at the injection site.

(1) Common in the elderly

Common (may affect up to 1 in 10 people)

  • Fever (2), chills, reactions at the injection site: redness (erythema), swelling, hardness (induration).

(2) Uncommon in the elderly

Uncommon (may affect up to 1 in 100 people)

  • Dizziness (3), diarrhea, feeling sick (nausea) (4), fatigue, reactions at the injection site: bruising (ecchymosis), itching (pruritus), and heat.

(3) Rare in adults (4) Rare in the elderly

  • Hot flushes: only observed in the elderly.
  • Swelling of the lymph nodes in the neck, armpit, or groin (lymphadenopathy): only observed in adults.

Rare (may affect up to 1 in 1,000 people)

  • Abnormal sensations, such as tingling or numbness (paresthesia), drowsiness, increased sweating (hyperhidrosis), unusual tiredness and weakness (asthenia), flu-like illness.
  • Joint pain (arthralgia), reactions at the injection site: only observed in adults.

Other side effects reported in children from 3 to 17 years of age

Very common (may affect more than 1 in 10 people)

  • Headache, muscle pain (myalgia), general feeling of being unwell (malaise), chills (5), reactions at the injection site: pain, swelling, redness (erythema) (5), hardness (induration) (5).

(5) Common in children from 9 to 17 years of age

Common (may affect up to 1 in 10 people)

  • Fever, bruising at the injection site (ecchymosis).

Uncommon (may affect up to 1 in 100 people) in children from 3 to 8 years of age:

  • Temporary decrease in the number of certain blood cells called platelets; when the number is low, it can lead to excessive bruising in the skin or bleeding (transient thrombocytopenia): only observed in a 3-year-old child
  • Crying, irritability
  • Dizziness, diarrhea, vomiting, upper abdominal pain, joint pain (arthralgia), fatigue, heat at the injection site.

Uncommon (may affect up to 1 in 100 people) in children from 9 to 17 years of age:

  • Diarrhea, itching at the injection site (pruritus).

Other side effects reported in children from 6 to 35 months of age

Very common (may affect more than 1 in 10 people):

  • Vomiting (1), muscle pain (myalgia) (2), irritability (3), loss of appetite (3), general feeling of being unwell (malaise) (2), fever.

(1) Uncommon in children from 24 to 35 months of age (2) Rare in children under 24 months of age

(3) Rare in children from 24 to 35 months of age.

  • Reactions at the injection site: pain/pain on palpation, redness (erythema).
  • Headache: only observed in children from 24 months of age onwards.
  • Drowsiness, abnormal crying: only observed in children under 24 months of age.

Common (may affect up to 1 in 10 people):

  • Chills: only observed in children from 24 months of age onwards.
  • Reactions at the injection site: hardness (induration), swelling, bruising (ecchymosis)

Uncommon (may affect up to 1 in 100 people):

  • Diarrhea, hypersensitivity.

Rare (may affect up to 1 in 1,000 people):

  • Flu-like illness, reactions at the injection site: rash, itching (pruritus).

In children from 6 months to 8 years of age who receive 2 doses, the side effects are similar after both the first and second doses. Some side effects may occur after the administration of the second dose in children from 6 months to 35 months of age.

These side effects, when observed, usually occurred within the first 3 days following vaccination and disappeared on their own within 1 to 3 days after starting. Most of these side effects were mild.

In general, side effects were less frequent in the elderly than in adults and children.

The following side effects have been observed after administering Vaxigrip. These side effects may also occur with Vaxigrip Tetra:

  • Pain along the nerve pathway (neuralgia), seizures (convulsions), neurological disorders that can result in stiffness in the neck, confusion, numbness, pain, and weakness of the limbs, loss of balance, loss of reflexes, paralysis of a part or all of the body (encephalomyelitis, neuritis, Guillain-Barré syndrome).
  • Inflammation of blood vessels (vasculitis) that can lead to skin rashes and, in very rare cases, temporary kidney problems.
  • Transient thrombocytopenia, lymphadenopathy, paresthesia in other age groups different from those described above for these side effects.

Reporting of side effects

If you or your child experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Vaxigrip Tetra

Keep this medicine out of the sight and reach of children.

Do not use this vaccine after the expiry date stated on the carton after EXP. The expiry date is the last day of the month stated.

Store in a refrigerator (2°C - 8°C). Do not freeze. Keep the syringe in the outer packaging to protect it from light.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Container Content and Additional Information

Vaxigrip Tetra Composition

  • The active ingredients are: Influenza virus (fractionated, inactivated) of the following strains*:
  • Strain similar to A/Victoria/4897/2022 (H1N1)pdm09: (IVR-238)........15 micrograms HA**
  • Strain similar to A/Croatia/10136RV/2023 (H3N2): (X-425)..............15 micrograms HA**
  • Strain similar to B/Austria/1359417/2021: B/Michigan/01/2021 ..…....15 micrograms HA**
  • B/Phuket/3073/2013..............................................................................15 micrograms HA**

Per 0.5 ml dose

  • grown in embryonated chicken eggs from healthy chickens

** hemagglutinin

This vaccine complies with the recommendations of the World Health Organization (Northern Hemisphere) and the decision of the European Union for the 2025-2026 campaign.

  • The other components are a buffer solution containing sodium chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate, potassium chloride, and water for injectable preparations.

Some components such as eggs (ovoalbumin, chicken proteins), neomycin, formaldehyde, or octoxinol-9 may be present in very small quantities (see section 2).

Product Appearance and Container Content

After careful shaking, the vaccine is a slightly whitish and opalescent liquid.

Vaxigrip Tetra is presented in a pre-filled syringe containing 0.5 ml of injectable suspension, with a fixed needle or without a needle (packs of 1, 10, or 20) or with a safety needle (in packs of 1 or 10).

Only some package sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Sanofi Winthrop Industrie

82 avenue Raspail

94250 Gentilly

France

Manufacturer:

The manufacturer responsible for batch release is:

Sanofi Winthrop Industrie

1541 avenue Marcel Mérieux

69280 Marcy l’Etoile

France

or

Sanofi Winthrop Industrie

Voie de l’Institut – Parc Industriel d’Incarville

B.P 101

27100 Val de Reuil

France

or

SANOFI-AVENTIS ZRT

Campona U.1 (Harbor Park )

Budapest 1225

Hungary

Local Representative

sanofi-aventis, S.A.

C/ Rosselló i Porcel, 21

08016 Barcelona

Spain

Tel: +34 93 485 94 00

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Member State

Name

  • Austria
  • Lithuania
  • Bulgaria, Croatia, Cyprus, Estonia, Finland, France, Greece, Iceland, Latvia, Malta, Poland, Portugal, Romania, Slovenia, Sweden, Netherlands
  • Denmark, Norway
  • Belgium, Luxembourg
  • Germany, Italy, Spain, Czech Republic, Slovakia, Hungary
  • Ireland, United Kingdom (Northern Ireland)

VaxigripTetra Injektionssuspension in einer Fertigspritze

VaxigripTetra injekcine suspensija užpildytame švirkšte

VaxigripTetra

Vaxigriptetra

Vaxigrip Tetra suspension injectable en seringue préremplie

Vaxigrip Tetra

Quadrivalent influenza vaccine (split virion, inactivated)

Date of the last revision of thisleaflet: May 2025

Other sources of information

You can access detailed and updated information about this medicinal product by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://vaxigriptetra-nh.info.sanofi

-------------------------------------------------------------------------------------------------------------------------

This information is intended only for doctors or healthcare professionals:

As with all injectable vaccines, medical treatment and appropriate supervision should be available in case of an anaphylactic episode following administration of the vaccine.

The vaccine should reach room temperature before use.

Shake before use.

The vaccine should not be used if it contains foreign particles in the suspension.

It should not be mixed with other medicines in the same syringe.

This vaccine should not be injected directly into any blood vessel.

See also section 3. How to use Vaxigrip Tetra.

Instructions for using the safety needle with the pre-filled Luer Lock syringe:

Image A: Safety Needle (inside the bar)

Image B: Components of the Safety Needle (prepared for use)

Medical needle with visible bar and gray central cap outlined, arrows point to each part of the device

Pre-filled syringe with exposed needle and retracted protector, arrows indicate safety device and protector

Step 1:To attach the needle to the syringe, remove the central cap to expose the needle bar, and gently turn the needle on the Luer Lock adapter of the syringe until you feel a slight resistance.

Step 2:Remove the protector from the safety needle. The needle is covered by the safety device and the protector.

Step 3:

A:Separate the safety device from the needle towards the body of the syringe at the angle shown.

B:Remove the protector in a straight line.

Hands holding syringe with needle inserted into skin, arrow indicates angle of insertion and another arrow direction of the plunger

Step 4:Once the injection is complete, lock (activate) the safety device using one of the three techniques illustrated (3) with one hand: activation with a surface, with the thumb, or with the index finger.

Note: Activation is verified by a "click" sound and/or tactile.

Syringe injecting medication into the skin with three steps indicated by check marks and flashes

Step 5:Visually inspect the activation of the safety device. The safety device must be completely locked (activated)as shown in figure C.

Figure D shows that the safety device is NOT completely locked (not activated).

Pre-filled syringe with plunger retracted and check mark in circle indicating correct position

Syringe with needle showing incorrect insertion at a right angle with a black cross indicating prohibition

Precaution: Do not attempt to unlock (deactivate) the safety device by forcing the needle out of the safety device.>

The disposal of unused vaccines and all materials that have come into contact with them will be carried out in accordance with local regulations.

Online doctors for VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE

Discuss questions about VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE?
VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE?
The active ingredient in VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE is influenza, inactivated, split virus or surface antigen. This information helps identify medicines with the same composition but different brand names.
Who manufactures VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE?
VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE is manufactured by Sanofi Winthrop Industrie. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to VAXIGRIP TETRA INJECTABLE SUSPENSION IN PRE-FILLED SYRINGE?
Other medicines with the same active substance (influenza, inactivated, split virus or surface antigen) include ADJUPANRIX 3.75 micrograms EMULSION AND SUSPENSION FOR INJECTABLE EMULSION, EFLUELDA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, EFLUELDA TETRA Injectable Suspension in Pre-filled Syringe. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media